| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2004 | US20040018525 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| 01/29/2004 | US20040018508 Surrogate antibodies and methods of preparation and use thereof |
| 01/29/2004 | US20040018327 Delayed release dosage forms |
| 01/29/2004 | US20040018261 Extract of Typhae Pollen traditional Chinese medicine consisting of flavonoids as active components includes kaempferol, quercetin and isorhamnetin; for lowering blood lipid level, preventing arteriosclerosis, coagulation |
| 01/29/2004 | US20040018253 Administering a drug for which major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation in combination with a CYP2D6 inhibitor |
| 01/29/2004 | US20040018251 Petasite extract is recovered from plant of the genus Petasites; effective in treating gastrointestinal diseases, asthmas, pollinosis, dysmenorrhea, eczemas, migraines, psoriasis and high blood pressure |
| 01/29/2004 | US20040018248 Composition containing statins and calcium for improved cardiovascular health |
| 01/29/2004 | US20040018245 Use of potassium for production of cardioplegic solution for prevention of stone heart development during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation |
| 01/29/2004 | US20040018243 Modulation of release from dry powder formulations |
| 01/29/2004 | US20040018242 Nanoparticulate nystatin formulations |
| 01/29/2004 | US20040018240 Method for producing preparation containing bioactive substance |
| 01/29/2004 | US20040018239 Pharmaceutical preparation containing copolyvidone |
| 01/29/2004 | US20040018235 An anticholesterol agents comprising pitavastatin, for treating hypercholesterolemia; time-release agents |
| 01/29/2004 | US20040018234 Four different dosage forms, two antibiotics inhibiting protein and non-protein synthesis, one comprising immediate release and sustained release, the other three has sustained release forms, twenty-four hour period; bacterial infections |
| 01/29/2004 | US20040018233 An expectorant drug delivery dosage forms comprises a sustained release portion and an immediate release portion; relieving from bronchial mucus accumulation |
| 01/29/2004 | US20040018232 Drugs comprising titanium dioxide pigments, titanium dioxide and/or iron oxide coated on inorganic substrates; use as food color |
| 01/29/2004 | US20040018230 Rehydrating a freeze dried liposome, encapsulating anesthetic bupivacaine, by agitating in water, washing the liposomes in hyperosmotic saline; storage stability, sustained release |
| 01/29/2004 | US20040018229 Insoluble drug delivery |
| 01/29/2004 | US20040018228 Compositions and methods for reducing scar tissue formation |
| 01/29/2004 | US20040018225 Triacylglycerols of enriched CLA content |
| 01/29/2004 | US20040018224 Supplementation of the diet with cholesterol results in a large stimulation of the plasma omega-3 fatty acid content |
| 01/29/2004 | US20040018221 A mixture of urea and vitamin E for treating dry skin, dermatitis, eczema, debridement; cosmetics, skin disorders |
| 01/29/2004 | US20040018218 Comprising sphingolipids used in cosmetics |
| 01/29/2004 | US20040018216 Substituted tropolone compounds, oral care compositions containing the same and methods of using the same |
| 01/29/2004 | US20040018202 Reverse a symptom including intravascular volume contraction, vasoconstriction and exaggerated myocardial function |
| 01/29/2004 | US20040018201 Method for controlling preeclampsia and eclampsia |
| 01/29/2004 | US20040018193 Rapid-acting broad spectrum protection against biological threat agents |
| 01/29/2004 | US20040018192 Integrin expression inhibitors |
| 01/29/2004 | US20040018179 Bioadhesive directed somatic cell therapy |
| 01/29/2004 | US20040018171 Biochemical conjugates comprising tumor necrosis factor or interferons and ligands of CD antigen receptors, used as anticarcinogenic agents |
| 01/29/2004 | US20040018169 Method for reducing oxalate |
| 01/29/2004 | US20040018158 Topical compositions including sunscreen compositions |
| 01/29/2004 | US20040018157 Oral composition providing enhanced oral hygiene properties |
| 01/29/2004 | US20040018153 The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1 7-((hydroxydi-2-thienylacetyl)oxy)-9, 9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane-bromide. |
| 01/29/2004 | US20040018152 Biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres, TECHNOSPHEREs tm ) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals |
| 01/29/2004 | US20040018151 Method of screening for compounds useful for promoting normal motor function in ALS patients is provided. The screening method comprises (a) administering a compound that is a anandamide/cannabinoid |
| 01/29/2004 | US20040018150 Screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for |
| 01/29/2004 | US20040016532 Cooling apparatus |
| 01/29/2004 | US20040016427 Method and apparatus for generating an aerosol |
| 01/29/2004 | DE10239612A1 Verfahren und Verbindungen zur Beeinflussung der Raumstruktur von GNB-Proteinen Methods and compounds for influencing the spatial structure of proteins GNB |
| 01/29/2004 | DE10233108A1 Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel Retarded painkillers containing Tilidin and a light stabilizer |
| 01/29/2004 | DE10233048A1 Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken Use of 1-phenyl-3dimethylamino-propane compounds for the therapy of depressive symptomatology |
| 01/29/2004 | DE10232113A1 Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel Vardenafil hydrochloride trihydrate containing medicines |
| 01/29/2004 | DE10230605A1 Substituierte Imidazotriazine Substituted imidazotriazines |
| 01/29/2004 | DE10230604A1 Heterocyclisch substituierte Imidazotriazine Heterocyclic substituted imidazotriazines |
| 01/29/2004 | DE10229872A1 Immunstimulation durch chemisch modifizierte RNA Immune stimulation by chemically modified RNA |
| 01/29/2004 | DE10229778A1 Neue Verwendung von Imidazotriazinonen New use of imidazotriazinones |
| 01/29/2004 | DE10229777A1 Indolin-Phenylsulfonamid-Derivate Indoline derivatives phenylsulfonamide |
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | DE10229180A1 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen Use of vasopeptidase inhibitors for the treatment of metabolic disorders, nephropathy, and diseases associated with AGE |
| 01/29/2004 | DE10224108A1 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung 1-dimethylamino-3- (3-methoxy-phenyl) -2-methyl-pentan-3-ol-containing sustained release Arzneimiitel |
| 01/29/2004 | CA2498982A1 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| 01/29/2004 | CA2496912A1 Methods and compositions for treating diabetes mellitis |
| 01/29/2004 | CA2496253A1 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 01/29/2004 | CA2493876A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 01/29/2004 | CA2493774A1 2,4-dihydroxybenzoic acid derivatives |
| 01/29/2004 | CA2493721A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 01/29/2004 | CA2493705A1 Conjugated linoleic acid powder |
| 01/29/2004 | CA2493645A1 Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
| 01/29/2004 | CA2493544A1 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 01/29/2004 | CA2493490A1 Treatment of depression secondary to pain (dsp) |
| 01/29/2004 | CA2493458A1 Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| 01/29/2004 | CA2493457A1 Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 01/29/2004 | CA2493384A1 Medicinal composition for treating arteriosclerosis |
| 01/29/2004 | CA2493341A1 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | CA2493234A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 01/29/2004 | CA2493227A1 Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates |
| 01/29/2004 | CA2493202A1 Antitumor compound and therapeutic uses thereof |
| 01/29/2004 | CA2493182A1 Compositions and methods for treating and preventing infection |
| 01/29/2004 | CA2493000A1 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
| 01/29/2004 | CA2492941A1 Remedy |
| 01/29/2004 | CA2492922A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 01/29/2004 | CA2492911A1 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
| 01/29/2004 | CA2492907A1 Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| 01/29/2004 | CA2492906A1 Materials and methods for treating hypercholesterolemia |
| 01/29/2004 | CA2492878A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 01/29/2004 | CA2492861A1 Process for preparing certain pyrrolotriazine compounds |
| 01/29/2004 | CA2492847A1 5-aryltetrazole compounds, compositions thereof, and uses therefor |
| 01/29/2004 | CA2492754A1 Compositions and products containing enantiomeric equol, and methods for their making |
| 01/29/2004 | CA2492726A1 4-amino-substituted pyrimidine derivatives |
| 01/29/2004 | CA2492665A1 Azaindole kinase inhibitors |
| 01/29/2004 | CA2492651A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | CA2492644A1 Polymorphic forms of nateglinide |
| 01/29/2004 | CA2492523A1 Novel inhibitors of ubiquitin isopeptidases |
| 01/29/2004 | CA2492456A1 Formulations and methods of administration of cephalotaxines, including homoharringtonine |
| 01/29/2004 | CA2492331A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | CA2492225A1 Combination therapy for the treatment of obesity |
| 01/29/2004 | CA2492224A1 Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutics |
| 01/29/2004 | CA2492211A1 Poly(potassium and sodium styrene sulfonate), its manufacture and its uses |
| 01/29/2004 | CA2492110A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 01/29/2004 | CA2491251A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/29/2004 | CA2491248A1 1-heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/29/2004 | CA2491131A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | CA2489982A1 Preparation of microbial oil containing polyunsaturated fatty acids |
| 01/29/2004 | CA2489008A1 Ghrelin-carrier conjugates |
| 01/29/2004 | CA2466288A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/28/2004 | EP1384774A1 Glycosaminoglycan/collagen complexes and use thereof |
| 01/28/2004 | EP1384726A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 01/28/2004 | EP1384722A1 Process for the production of 2-(5-methyl-4-oxazolyl)acetates |
| 01/28/2004 | EP1384721A1 Stable amorphous calcium pseudomonate and processes for the preparation thereof |